The China Mail - The quest for a universal coronavirus vaccine

USD -
AED 3.672945
AFN 71.515562
ALL 86.94961
AMD 389.939958
ANG 1.80229
AOA 915.999667
ARS 1172.9892
AUD 1.560185
AWG 1.8
AZN 1.687821
BAM 1.720875
BBD 2.018575
BDT 121.46782
BGN 1.725883
BHD 0.37691
BIF 2935
BMD 1
BND 1.306209
BOB 6.908081
BRL 5.674401
BSD 0.99974
BTN 84.489457
BWP 13.685938
BYN 3.271726
BYR 19600
BZD 2.008192
CAD 1.37935
CDF 2872.999879
CHF 0.825695
CLF 0.024788
CLP 951.229649
CNY 7.27135
CNH 7.270995
COP 4243.1
CRC 504.973625
CUC 1
CUP 26.5
CVE 97.62505
CZK 22.028021
DJF 177.720538
DKK 6.590695
DOP 58.849845
DZD 132.651987
EGP 50.839498
ERN 15
ETB 131.849601
EUR 0.883015
FJD 2.25945
FKP 0.7464
GBP 0.750775
GEL 2.744963
GGP 0.7464
GHS 14.125014
GIP 0.7464
GMD 71.502639
GNF 8655.000086
GTQ 7.69911
GYD 209.794148
HKD 7.755845
HNL 25.824976
HRK 6.653403
HTG 130.612101
HUF 357.316013
IDR 16554.05
ILS 3.63992
IMP 0.7464
INR 84.561198
IQD 1310
IRR 42112.49408
ISK 128.649713
JEP 0.7464
JMD 158.264519
JOD 0.709199
JPY 143.008025
KES 129.497429
KGS 87.450184
KHR 4001.999982
KMF 434.49611
KPW 899.962286
KRW 1424.74995
KWD 0.306504
KYD 0.833176
KZT 513.046807
LAK 21614.999723
LBP 89600.000276
LKR 299.271004
LRD 199.577898
LSL 18.629585
LTL 2.95274
LVL 0.60489
LYD 5.454983
MAD 9.26875
MDL 17.160656
MGA 4509.999741
MKD 54.316596
MMK 2099.391763
MNT 3573.279231
MOP 7.987805
MRU 39.750136
MUR 45.159946
MVR 15.410097
MWK 1735.999892
MXN 19.613201
MYR 4.314499
MZN 64.000264
NAD 18.629738
NGN 1602.529753
NIO 36.697423
NOK 10.402335
NPR 135.187646
NZD 1.68454
OMR 0.384943
PAB 0.99974
PEN 3.6615
PGK 4.030499
PHP 55.780526
PKR 280.898478
PLN 3.78005
PYG 8007.144837
QAR 3.640973
RON 4.395801
RSD 103.43097
RUB 82.013774
RWF 1415
SAR 3.751221
SBD 8.361298
SCR 14.237635
SDG 600.502786
SEK 9.662047
SGD 1.305725
SHP 0.785843
SLE 22.790211
SLL 20969.483762
SOS 571.999643
SRD 36.846978
STD 20697.981008
SVC 8.747487
SYP 13001.4097
SZL 18.630308
THB 33.430038
TJS 10.537222
TMT 3.5
TND 2.96375
TOP 2.342099
TRY 38.52375
TTD 6.771697
TWD 32.047014
TZS 2690.000195
UAH 41.472624
UGX 3662.201104
UYU 42.065716
UZS 12945.00049
VES 86.73797
VND 26005
VUV 120.409409
WST 2.768399
XAF 577.175439
XAG 0.030629
XAU 0.000305
XCD 2.70255
XDR 0.71673
XOF 576.000137
XPF 105.649908
YER 244.950087
ZAR 18.60662
ZMK 9001.201184
ZMW 27.817984
ZWL 321.999592
  • CMSC

    -0.2300

    22.01

    -1.04%

  • SCS

    -0.0900

    9.92

    -0.91%

  • RYCEF

    -0.2500

    10

    -2.5%

  • RBGPF

    63.0000

    63

    +100%

  • CMSD

    -0.0500

    22.3

    -0.22%

  • NGG

    -0.0400

    73

    -0.05%

  • RIO

    -1.4800

    59.4

    -2.49%

  • RELX

    0.8400

    54.63

    +1.54%

  • AZN

    0.0800

    71.79

    +0.11%

  • GSK

    0.8800

    39.85

    +2.21%

  • BCC

    -1.2200

    93.28

    -1.31%

  • JRI

    -0.0200

    12.91

    -0.15%

  • BCE

    0.3300

    22.25

    +1.48%

  • VOD

    0.1800

    9.76

    +1.84%

  • BTI

    0.6900

    43.55

    +1.58%

  • BP

    -0.6100

    27.46

    -2.22%

The quest for a universal coronavirus vaccine
The quest for a universal coronavirus vaccine / Photo: © AFP/File

The quest for a universal coronavirus vaccine

As vaccine makers rush to stamp out new Covid-19 variants, some scientists have set their sights higher, aiming for a universal coronavirus vaccine that could tackle any future strains and possibly even stave off another pandemic.

Text size:

Since the race for a first Covid jab supercharged a new generation of vaccine technology, there have been numerous efforts to develop pan-coronavirus immunisation.

Drew Weissman of the University of Pennsylvania, who was a pioneer of the mRNA technology used in Pfizer's Covid vaccine, is leading one such project.

He said the problem with updating current vaccines to target all existing strains -- a plan announced by Pfizer earlier this month -- is that "new variants are going to appear every three or six months".

After more than two years simply trying to infect more people, he said, the virus is now starting to mutate specifically to get around the immunity gained from vaccines -- much as influenza's constant changing requires an updated shot every year.

"That makes it a little bit trickier, because now you're fighting head-to-head with the virus," Weissman told AFP.

So his team is working on a pan-coronavirus vaccine, which he said has tested well so far.

They are trying to find "highly conserved epitope sequences" -- more integral parts of the virus that cannot mutate readily because it would die without them.

But it's not going to be easy.

"We may have a universal vaccine in two or three years, but we're going to have to keep working on it and changing it over time to keep ahead of the virus," Weissman said.

- Expanding ambitions -

Covid was not the first coronavirus to jump from animals to humans this century: its older relative SARS killed nearly 800 people from 2002-2004, and the Middle East Respiratory Syndrome (MERS) followed in 2012.

When US-based biotech firm VBI Vaccines announced its pan-coronavirus project in the early days of the pandemic in March 2020, it targeted all three.

Francisco Diaz-Mitoma, VBI's chief medical officer, explained the premise by likening each antigen of their proposed vaccine to one of the three primary colours.

The firm hopes to provide antibodies not just for these three -- but also for "the various shades of orange, green, and purple found in between".

"In other words, we are trying to teach the immune system to expand upon the variations of virus it is capable of 'seeing' from the start," he told AFP.

He said VBI's vaccine had shown promising results so far -- including in bats and pangolins -- with clinical studies hoped to start in the coming months ahead of results in early 2023.

The ferritin nanoparticle vaccine effort led by Barton Haynes, director of Duke University's Human Vaccine Institute, has received funding from the US National Institute of Allergies and Infectious Diseases (NIAID).

He told AFP this vaccine, which targets SARS-like viruses but not a broader range of coronaviruses like MERS, had been shown to work well against Omicron.

- 'Leaping one step ahead' -

Pamela Bjorkman of the California Institute of Technology said a true pan-coronavirus vaccine was probably not realistic because there are so many lineages -- some which include common colds.

Her project uses a mosaic nanoparticle approach to target the B lineage of betacoronaviruses, which includes the original SARS-CoV and SARS-CoV-2, the virus that causes the disease Covid.

Bjorkman told AFP that even the "quest" for this specific lineage was comparable to the "many years of effort to make a universal influenza vaccine."

Like Haynes, she said the wide availability of a vaccine depended on how quickly they could begin human trials.

Even if none of the current pan-coronavirus vaccine projects are likely to be rolled out in the next year, their eventual arrival could change the world's relationship with Covid.

"If a pan-coronavirus vaccine is successfully able to establish a broader foundational immunity against coronaviruses, it would allow us, as a global society, to go from being one step behind, to leaping one step ahead of the pandemic," Diaz-Mitoma said.

The broadening horizons of vaccine research could also be one way Covid has forced the world to better prepare for the threat of even worse pandemics ahead.

The US-based Coalition for Epidemic Preparedness Innovations (CEPI) has earmarked $200 million (185 million euros) for pan-coronavirus research.

But it also has a $3.5 billion (3.2 billion euro) plan it hopes will help develop a vaccine targeting "the next Disease X" within 100 days of it emerging -- regardless of whether it is a coronavirus.

D.Peng--ThChM